Sage Therapeutics - Timberline Construction
Sage Therapeutics Restructures To Support ZURZUVAE Launch | Contract Pharma
Sage Therapeutics fires 40% of staff after FDA rejected MDD bid - Pharmaceutical Technology
/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/5L4UQNLAORLRMH6HCPVSUTPQUE.JPEG "Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe")
Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe
Sage Therapeutics
Sage tumbles to record low on clinical depression pill setback | Reuters
While Sage Therapeutics sees a window for depression drug, market is skeptical - MedCity News
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
Sage Therapeutics stock falls after stock offering, Q3 miss | Seeking Alpha
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Layoffs as Sage Therapeutics reshuffles CNS pipeline
Sage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus - Tinnitus Treatment Report
Sage Therapeutics CEO: Mental health is integral to returning to work
Sage Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:SAGE) | Seeking Alpha
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
Biotech layoffs 2023: Sage Therapeutics cuts nearly half its staff in wake of partial FDA rejection - Boston Business Journal
Sage Stock: FDA Documents Suggest Its Battle In Depression Will Be Trickier Than Expected | Investor's Business Daily
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 | Reuters
Sage Therapeutics Archives - DelveInsight
Sage Therapeutics CEO on drugs in development, addressing mental health
Sage Therapeutics plunges after FDA decision on depression drug
